Management

The management team is made up of proven industry veterans who have successfully started up and managed biotechnology organizations and companies. The team has a proven track record developing anticancer and infectious disease drugs and also commercializing and taking drugs through the entire development process.

Frank K. Bedu-Addo, Ph.D., President and CEO. - Dr. Bedu-Addo is a veteran executive and bio-entrepreneur with experience successfully starting and growing biotechnology organizations. He has been responsible for the development and implementation of both operational and drug development strategies, supervising and managing both large organizations as well as emerging biotechnology companies. Dr. Bedu-Addo was a founding and senior executive member of KBI BioPharma, Inc. As Vice President of Drug Development he oversaw all business and drug development operations. Before being hired by KBI, he successfully started and managed Cardinal Health’s east coast biotechnology drug development operations. Prior to Cardinal Health, Dr. Bedu-Addo was also an Associate Director at Akzo-Nobel, Senior Scientist at Elan (The Liposome Co.), and Principal Scientist at Schering-Plough. In these positions he participated in the development of numerous drugs, including antiviral and anticancer drugs. He serves on the board of directors of BioConvergence, LLC, an early stage biotechnology company. Dr. Bedu-Addo obtained his M.S. in chemical engineering and Ph.D. in pharmaceutics from the University of Pittsburgh.

Gregory L. Conn, Ph.D., Chief Scientific Officer. - Dr. Conn has over 35 years of drug development expertise, including the development of antiviral and anticancer drugs. Dr. Conn has experience taking drugs through complete development and commercialization. He is a graduate of the Albert Einstein College of Medicine, where he obtained both his M.S. and Ph.D. in biochemistry. Dr. Conn started his professional career at Merck, Sharpe and Dohme. He was a leading scientist at Regeneron Pharmaceuticals, where he established and headed various groups in the Cell and Molecular Biology and Drug Discovery departments. He was a Director in the Process Development department at Covance Biotechnology Services Inc., a contract research and development and drug manufacturing organization. He supervised both the Analytical Development teams which were responsible for all drug characterization, method development and drug stability studies and program teams developing drug manufacturing processes. He has expertise across all phases of the drug development process including commercialization of drugs, FDA and regulatory requirements. He is also the co-inventor of 8 drug patents.